The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | ARC-8: AB680 + zimberelimab for first-line mPDAC
Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, provides an update on the ARC-8 trial (NCT04104672), a Phase I/Ib study to evaluate the safety and tolerability of AB680, a potent and selective inhibitor of CD73, plus chemotherapy and zimberelimab, an anti-PD-1 antibody, in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
